Literature DB >> 16104987

Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study.

J-R Zahar1, H Farhat, E Chachaty, P Meshaka, S Antoun, G Nitenberg.   

Abstract

Recent studies have shown that anaerobes account for 0.5-9% of all episodes of bacteraemia in hospitalised patients, with variations according to geographical location and demographic characteristics, most notably age, but few data are available for cancer patients. This study investigated retrospectively the incidence of anaerobic bacteraemia in cancer patients who received non-surgical treatment over a 6-year period at a tertiary oncology centre. Gastrointestinal (27%) and haematological (29%) malignancies were the most common underlying diseases. Among 45 isolates of anaerobic bacteria recovered from 45 patients, Bacteroides spp. and Clostridium spp. were the most frequent pathogens (60% and 22%, respectively). Twenty episodes of bacteraemia were polymicrobial, most frequently with aerobic Gram-negative bacilli (18 cases). The mortality rate for patients with adequate antimicrobial therapy from the outset was 14%, compared with 63% for patients who were not treated adequately at any time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16104987     DOI: 10.1111/j.1469-0691.2005.01214.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Relevance of routine use of the anaerobic blood culture bottle.

Authors:  Patrick Grohs; Jean-Luc Mainardi; Isabelle Podglajen; Xavier Hanras; C Eckert; A Buu-Hoï; E Varon; Laurent Gutmann
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

Review 3.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Are incidence and epidemiology of anaerobic bacteremia really changing?

Authors:  A Vena; P Muñoz; L Alcalá; A Fernandez-Cruz; C Sanchez; M Valerio; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-28       Impact factor: 3.267

5.  Population-based assessment of the incidence, risk factors, and outcomes of anaerobic bloodstream infections.

Authors:  J T Ngo; M D Parkins; D B Gregson; J D D Pitout; T Ross; D L Church; K B Laupland
Journal:  Infection       Date:  2013-01-05       Impact factor: 3.553

6.  Life-threatening clostridial sepsis in a postmenopausal patient with degenerating uterine leiomyoma.

Authors:  Christopher S Bryant; Latoya Perry; Jay P Shah; Sanjeev Kumar; Gunter Deppe
Journal:  Case Rep Med       Date:  2010-05-30

7.  Gas-forming liver abscess associated with rapid hemolysis in a diabetic patient.

Authors:  Miwa Kurasawa; Takashi Nishikido; Junko Koike; Shin-Ichi Tominaga; Hiroyuki Tamemoto
Journal:  World J Diabetes       Date:  2014-04-15

8.  Clostridium glycolicum bacteremia in a bone marrow transplant patient.

Authors:  Sameer Elsayed; Kunyan Zhang
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

9.  Application of MALDI-TOF MS to assess clinical characteristics, risk factors, and outcomes associated with anaerobic bloodstream infection: a retrospective observational study.

Authors:  Tsuyoshi Watanabe; Yuki Hara; Yusuke Yoshimi; Waka Yokoyama-Kokuryo; Yoshiro Fujita; Masamichi Yokoe; Yoshinori Noguchi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-09       Impact factor: 3.944

10.  Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System.

Authors:  Abigail V Sharrock; Sarah P McManaway; Michelle H Rich; Jeff S Mumm; Ian F Hermans; Moana Tercel; Frederik B Pruijn; David F Ackerley
Journal:  Front Pharmacol       Date:  2021-06-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.